Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 3,000 shares, a decrease of 80.9% from the March 15th total of 15,700 shares. Based on an average trading volume of 84,800 shares, the short-interest ratio is presently 0.0 days. Currently, 0.2% of the shares of the stock are sold short.

Virax Biolabs Group Stock Performance

Shares of Virax Biolabs Group stock opened at $0.78 on Friday. Virax Biolabs Group has a fifty-two week low of $0.70 and a fifty-two week high of $8.54. The firm has a 50-day simple moving average of $0.84 and a two-hundred day simple moving average of $1.63.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Armistice Capital LLC acquired a new stake in Virax Biolabs Group in the 1st quarter valued at about $1,043,000. Legal & General Group Plc purchased a new position in shares of Virax Biolabs Group during the 4th quarter worth approximately $73,000. UBS Group AG purchased a new position in shares of Virax Biolabs Group during the 3rd quarter worth approximately $38,000. Finally, Virtu Financial LLC purchased a new position in shares of Virax Biolabs Group during the 4th quarter worth approximately $35,000. Institutional investors and hedge funds own 8.61% of the company’s stock.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.